



July 15, 2026

Notice of Execution of Master Agreement with MI Clinic and Completion of RI Sales Business Notification

-Toward Establishing a Management Framework for Investigational Radiopharmaceuticals in Theranostics -

Medical Corporation MI Clinic (head office: Toyonaka, Osaka) and Micron, Inc. (head office: Minato-ku, Tokyo; hereinafter "Micron") have entered into a comprehensive master service agreement for radiopharmaceutical-related services.

This agreement establishes the basic framework for appropriately coordinating MI Clinic's specialized expertise in the in-house manufacture and operation of radiopharmaceuticals with Micron's track record and know-how in clinical research, clinical trial support, and imaging analysis.

In addition, Micron has completed the notification for its radioisotope ("RI") sales business under the Act on Prevention of Radiation Hazards due to Radioisotopes, etc. (the "RI Act"). This enables Micron to meet the regulatory requirements for the sale, management, and delivery of investigational radiopharmaceuticals.

Based on this agreement and in collaboration with MI Clinic, Micron has secured an emergency storage framework for investigational radiopharmaceuticals and has strengthened its management and record-keeping systems.. Micron will ensure traceability and compliance with applicable laws and regulations and will support GCP-compliant investigational product management.

In recent years, The number of planned clinical trials in the field of theranostics has been increasing in Japan.. At the same time, the distribution and management frameworks for investigational radiopharmaceuticals cannot yet be said to be sufficiently established. This initiative is intended to help address such infrastructure-related challenges.

Going forward, Micron will continue to expand its services for pharmaceutical companies by strengthening its capabilities in the management and operation of investigational radiopharmaceuticals to support clinical trials in the field of theranostics. Through this initiative, Micron also aims to provide international companies developing theranostic radiopharmaceuticals with a reliable local support framework for conducting clinical trials in Japan, built on regulatory compliance and quality assurance.

Company name Company Information

Clinic Director	Atsuya Okada
Head Office	1-12-13 Shoji, Toyonaka City, Osaka Prefecture
Established	October 1, 2005
Business Contents	• Provision of high-quality medical care and contribution to regional healthcare • PET-CT diagnostic imaging, including FDG, PSMA, and amyloid imaging • Diagnostic imaging using 3T MRI and 64-slice CT • Contract diagnostic imaging services for clinical research, including clinical trials • Contract manufacturing of PET diagnostic agents for clinical research • Cancer screening and dementia screening
URL	https://www.jinsen-pet.jp/index.html

Micron, Inc. Company Information

President & CEO	Hiroaki Suzuki
Head Office	2-13-40 Konan, Minato-ku, Tokyo, Japan
Established	October 3, 2005
Business Contents	- Supports development of pharmaceuticals, diagnostics, medical devices, and biomarkers by utilizing imaging technologies - Clinical development support (monitoring, quality control, imaging core lab, image analysis, central imaging review etc.) - PET tracer manufacturing support, - Consulting for clinical development
URL	https://microncro.com/en/

Contact

Micron, Inc.

E-mail	info@micron-kobe.com
URL	https://microncro.com/en/